Dr. Camprodon is Chief of the Division of Neuropsychiatry at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School.
Clinically, he is the founding director of the MGH Transcranial Magnetic Stimulation (TMS) clinical service, a member of the Psychiatric Neurosurgery Committee and an attending physician in the departments of Psychiatry (Neuropsychiatry) and Neurology (Cognitive and Behavioral Neurology). He is board-certified in Psychiatry and Behavioral Neurology & Neuropsychiatry.
Scientifically, Dr. Camprodon directs the Laboratory for Neuropsychiatry and Neuromodulation and is in the executive committee of the MGH Interdisciplinary Brain Center. His research uses multimodal combinations of neuroimaging and brain stimulation to investigate neural circuitry and plasticity in a translational manner. His laboratory works with a wide range of noninvasive and invasive neuromodulation techniques including transcranial electrical current stimulation (tECS), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and deep brain stimulation (DBS) among others. He also uses functional and structural MRI and EEG, in addition to innovative combinations of TMS and tDCS with neuroimaging.
Dr. Camprodon is interested in understanding basic circuit properties of human neural networks and how maladaptive plastic changes lead to neuropsychiatric disorders. The scope of his research includes basic, translational and clinical projects focused on circuit neuroscience. Current projects address the anatomy and physiology of disease-relevant networks as well as the investigation of pathophysiological mechanisms at the circuit level, with an emphasis on transdiagnostic processes and the role of plasticity. Critical translational efforts are geared towards applying the paradigms and methods of human systems neuroscience to develop practical and high-impact clinical tools with the potential to change how we practice medicine: e.g. identify biomarkers and predictors, discover treatment targets and design individualized precision therapies with an emphasis on device-based neuromodulation.